Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Champions Oncology's selling, general, & admin. expense for the
three
months ended in Jan. 2026 was $5.64 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jan. 2026 was $19.87 Mil.
Champions Oncology (NAS:CSBR) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Champions Oncology Selling, General, & Admin. Expense Related Terms
Champions Oncology Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for Champions Oncology's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology Selling, General, & Admin. Expense Chart
CSBR vs SEER, RLYB, FBIO: Selling, General, & Admin. Expense Comparison
For the Biotechnology subindustry, Champions Oncology's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology Selling, General, & Admin. Expense vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Champions Oncology's Selling, General, & Admin. Expense falls into.
Champions Oncology Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of $19.87 Mil mean?
Champions Oncology (CSBR) has a Selling, General, & Admin. Expense of $19.87 Mil as of Jan. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Champions Oncology and its competitors.
Is Champions Oncology's Selling, General, & Admin. Expense too high?
Champions Oncology's current Selling, General, & Admin. Expense is $19.87 Mil. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Selling, General, & Admin. Expense compare to SEER and RLYB?
Champions Oncology's Selling, General, & Admin. Expense of $19.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Champions Oncology and its competitors. Champions Oncology's current Selling, General, & Admin. Expense is $19.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.67, compared to a current price of $6.12 — trading 8.2% below its estimated fair value. The current Selling, General, & Admin. Expense is $19.87 Mil. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Selling, General, & Admin. Expense is $19.87 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued.
The current stock price of $6.12 is trading 8.2% below its estimated GF Value™ of $6.67.
GuruFocus considers Champions Oncology to be Fairly Valued.
Key valuation signals for CSBR:
Selling, General, & Admin. Expense: $19.87 Mil
GF Value™: $6.67 vs. price of $6.12 (8.2% below fair value)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score
Get the complete analysis for CSBR
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 
